Allergan, AstraZeneca Partner for Antibiotic for Drug-Resistant Infections
Allergan has entered into a global agreement with AstraZeneca to develop and commercialize ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam. Together, the two companies will evaluate the combination to treat serious infections caused by metallo Î²lactamase MBL-producing Gram-negative pathogens, a difficult-to-treat sub-type of carbapenem-resistant Enterobacteriaceae (CRE), for which there are currently very limited treatments, thus presenting a new treatment option for patients with MBL-producing pathogens. Under the terms of the agreement, Allergan will maintain commercialization rights in the US and Canada, and AstraZeneca will maintain commercialization rights in all other countries.
ATM-AVI is the first drug candidate to be developed under a public-private partnership agreement between AstraZeneca and the Biomedical Advanced Research and Development Authority (BARDA), a part of the US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response. Announced in September 2015, the goal of this strategic alliance is to develop a portfolio of drug candidates over the next five years with dual uses in treating illnesses caused by bioterrorism agents and antibiotic-resistant infections.
Aztreonam is not inactivated by MBLs, as a single agent it has limited utility because the vast majority of MBL-producing pathogens also express serine-Î²-lactamases that can inactivate it. With avibactam’s ability to inhibit many serine-Î²-lactamase enzymes, aztreonam’s activity is restored against pathogens that co-produce MBLs and serine enzymes, thus presenting a new treatment option for patients.
The European Union’s Innovative Medicines Initiative (IMI), a partnership between the European Union and the European pharmaceutical industry, is currently supporting the Phase II clinical study of ATM-AVI in Europe. BARDA and AstraZeneca are supporting global Phase III clinical development needed to apply for regulatory approval of ATM-AVI.